FDA Approves First Therapy for Children and Adults with TK2d

The U.S. Food and Drug Administration has approved KYGEVVI (doxecitine and doxribtimine), marking the first and only approved treatment for thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients whose symptoms began at age 12 or younger. UCB, the developer, said it expects KYGEVVI to be commercially available in the United States in the first quarter of 2026, and that this marks the company’s third rare-disease approval in under three years.

The approval rests on a body of evidence that includes one Phase II clinical trial (Trial 1, NCT03845712), two retrospective chart review studies (Study 1 and Study 2, NCT03701568 and NCT05017818) and an expanded access program (NCT06590493). Company-reported data indicated KYGEVVI reduced the overall risk of death from treatment initiation by 86%, a sizable effect in a condition with historically poor outcomes and few therapeutic options.

TK2 deficiency is a rare mitochondrial DNA maintenance disorder that can present in infancy or childhood with progressive muscle weakness and respiratory compromise. For families and clinicians, the approval ends a long era without a targeted, approved therapy and could redefine standards of care. The expanded access program that contributed data to the approval underscores the urgency clinicians and patients felt in seeking experimental options while awaiting definitive therapies.

Regulators frequently rely on smaller or nonrandomized datasets when approving drugs for rare diseases where large randomized trials may be infeasible. The evidence package supporting KYGEVVI reflects that reality, combining prospective trial data with retrospective and expanded-access experience. While the mortality reduction reported is striking, specialists caution that longer-term follow-up and broader real-world evidence will be important to clarify durability of benefit, safety in diverse patient subgroups, and effects on functional outcomes such as mobility and respiratory support requirements.

Beyond clinical questions, the approval spotlights systemic challenges in rare-disease care. Access to an approved medication does not guarantee equitable access to treatment. Patients with ultra-rare conditions often face delayed diagnosis, limited specialist availability, and substantial financial barriers. Payers will now confront decisions about coverage and reimbursement for a therapy likely to be costly to develop and produce. Policymakers and patient advocates will press for transparent pricing, coverage policies that do not penalize those diagnosed late, and robust post-approval surveillance to ensure safety and effectiveness across populations.

UCB’s timetable to make KYGEVVI available by early 2026 gives clinicians and health systems time to prepare logistics for prescribing, monitoring and supply. The approval is a milestone for the TK2d community and for rare-disease therapeutics more broadly, but translating regulatory success into equitable patient benefit will require coordinated action from manufacturers, clinicians, insurers and regulators. Long-term monitoring and commitments to affordability will determine whether the promise of KYGEVVI becomes tangible relief for patients and families who have long navigated a landscape of few options and high uncertainty.